Further, administration of α-TGF-β appeared to ameliorate the fibrotic milieu of STAMTM model of murine HCC and lead to enhanced distribution of CD8+ T cells, thereby highlighting the potential benefits of combining anti-fibrotic therapies with immune checkpoint inhibitors to treat HCC. Here, CD8A is linked to hepatocellular carcinoma.